U.S. pharma huge copyright scrapped two experimental weight loss drugs final yr—a after-day by day tablet, lotiglipron, because of elevated liver enzymes in addition to a two times-day by day tablet, danuglipron, resulting from potent side effects—but CEO Albert Bourla has said the company is decided to “Perform and win” while in the weight